Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENBREL vs AVSOLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
Rheumatoid arthritis (moderate to severe active RA in adults, alone or with methotrexate),Polyarticular juvenile idiopathic arthritis (moderate to severe active JIA in patients aged 2 years and older),Psoriatic arthritis (active Ps A in adults),Ankylosing spondylitis (active AS in adults),Plaque psoriasis (moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy)
Crohn's disease (moderate to severe, fistulizing),Pediatric Crohn's disease (moderate to severe),Ulcerative colitis (moderate to severe),Pediatric ulcerative colitis (moderate to severe),Rheumatoid arthritis (in combination with methotrexate),Ankylosing spondylitis,Psoriatic arthritis,Plaque psoriasis (chronic severe)
50 mg subcutaneous injection once weekly
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Metabolism is via peptide hydrolysis and protein catabolism; no significant cytochrome P450 involvement.
Infliximab is a monoclonal antibody; metabolism is via catabolism into peptides and amino acids through general protein degradation pathways (reticuloendothelial system). No involvement of CYP450 enzymes.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
~96% bound, primarily to albumin and to a lesser extent to other plasma proteins.
Predominantly bound to soluble TNF-alpha; no specific plasma protein binding (e.g., albumin) is reported; the complex is cleared, so free drug binding is low.
Approximately 0.18 L/kg (adults), indicating limited distribution primarily within the vascular and interstitial spaces; not extensively distributed into tissues.
Volume of distribution is approximately 0.04–0.06 L/kg, indicating limited tissue distribution primarily within the vascular space.
Subcutaneous: approximately 59% (range 50–76%) after a single 25 mg dose; absolute bioavailability not established for IV route; intramuscular route not recommended.
Bioavailability is 100% after intravenous infusion; no other routes are clinically relevant.
No dose adjustment required for renal impairment. Not studied in patients with severe renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment. Not studied in patients with severe hepatic impairment.
No formal studies; use caution in hepatic impairment.
For juvenile idiopathic arthritis (JIA) patients aged 2 years and older: 0.8 mg/kg (max 50 mg) subcutaneously once weekly.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; approved for ages 6 years and older.
No specific dose adjustment based on age alone; monitor for infections and adverse effects as elderly patients may have increased susceptibility.
No specific dose adjustment; monitor for infections and adverse effects.
Serious infections, including tuberculosis (TB), invasive fungal infections, and other opportunistic infections, have been reported. Patients should be screened for TB prior to therapy. Discontinue if serious infection develops. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections) leading to hospitalization or death; increased risk of lymphoma and other malignancies, including fatal hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease.
Risk of serious infections (including TB, bacterial sepsis, invasive fungal infections),Hepatitis B reactivation,Malignancies (including lymphoma, leukemia, and other malignancies),Congestive heart failure (new onset or exacerbation),Demyelinating disorders (e.g., multiple sclerosis, optic neuritis),Hematologic abnormalities (including pancytopenia and aplastic anemia),Hypersensitivity reactions,Live vaccines should not be administered concurrently
Risk of serious infections (screen for latent TB and treat before initiation, monitor for active infections),Hypersensitivity reactions (including anaphylaxis, serum sickness),Hepatotoxicity (including hepatic failure, acute liver injury),Reactivation of hepatitis B virus,Hematologic toxicity (pancytopenia, leukopenia),Neurologic events (demyelinating disorders, seizure, optic neuritis),Heart failure exacerbation,Lupus-like syndrome,Immunogenicity (development of anti-drug antibodies leading to infusion reactions and loss of response),Malignancy (especially lymphoma, leukemia, melanoma, and Merkel cell carcinoma)
Known hypersensitivity to etanercept or any component of the product,Sepsis or active infections (including chronic or localized infections)
History of severe hypersensitivity to infliximab or any murine proteins,Moderate to severe heart failure (NYHA class III/IV),Active serious infections (including sepsis, abscesses, tuberculosis, opportunistic infections),Concurrent use with abatacept or anakinra (increased risk of infection)
No specific food interactions have been reported with ENBREL. However, because ENBREL affects the immune system, patients should practice food safety to reduce infection risk (e.g., avoid undercooked meats, unpasteurized dairy).
No known food interactions. AVSOLA is administered intravenously, and its absorption is not affected by oral intake. However, patients should maintain a balanced diet to support immune function.
Etanercept is an Ig G1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birth defects or miscarriage, but there is a potential for immunosuppression in the neonate if used in the third trimester. Animal studies show no teratogenicity.
AVSOLA (infliximab-axxq) is a monoclonal antibody. Ig G crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated with low risk of major malformations. Second and third trimester exposure may increase risk of fetal immunosuppression, including neonatal lymphopenia, and vaccination risks. Avascular necrosis and congenital anomalies have been reported post-marketing but causal relationship not established. Avoid live vaccines in infants exposed in utero for 6 months.
Etanercept is excreted into breast milk in low amounts (M/P ratio approximately 0.001). Oral bioavailability is poor due to protein nature, so infant exposure is minimal. Compatible with breastfeeding, but monitor infant for infection or other adverse effects.
Infliximab is excreted in breast milk in small amounts; M/P ratio (milk to plasma ratio) is approximately 0.001-0.002. Oral bioavailability in infants is low due to gastrointestinal degradation. Limited data show no adverse effects in breastfed infants. However, consider maternal dosage, infant age, and risk of immunosuppression. Benefit of breastfeeding likely outweighs minimal risk.
No standard dose adjustment recommended. However, due to increased clearance in later pregnancy, some clinicians may consider increasing dose or shortening interval to maintain efficacy, especially in the third trimester.
Pharmacokinetics of infliximab may be altered due to increased plasma volume, renal clearance, and third-spacing during pregnancy. However, no specific dose adjustment guidelines are established. Most studies recommend maintaining standard dosing throughout pregnancy to ensure therapeutic levels. Monitor clinical response and consider therapeutic drug monitoring if needed. Postpartum, no dose adjustment required, but reassess for disease flare.
ENBREL (etanercept) is a TNF-alpha inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. Monitor for infections, including tuberculosis reactivation. Do not administer live vaccines during therapy. Injection site reactions are common. If switching from other TNF inhibitors, consider washout period. ENBREL can be used in combination with methotrexate but avoid with other biologics.
AVSOLA (infliximab-axxq) is a biosimilar to Remicade. Pre-medicate with antihistamines and acetaminophen to reduce infusion reactions. Screen for latent TB (PPD or IGRA) and HBV before initiation. Do not administer live vaccines during therapy. Monitor for signs of infection, including opportunistic infections like histoplasmosis. Discontinue if symptoms of lupus-like syndrome or severe hepatotoxicity occur. Infusion reactions may occur up to 2 hours post-infusion; have emergency equipment available.
ENBREL is given as a subcutaneous injection, typically once or twice weekly. Proper injection technique and rotation of sites are important.,Do not take live vaccines (e.g., MMR, nasal flu, varicella) while on ENBREL.,Seek medical attention if you develop signs of infection (fever, chills, cough) or allergic reactions (rash, difficulty breathing).,Report any new or worsening neurological symptoms, such as numbness, tingling, or vision changes.
AVSOLA is given as an IV infusion over at least 2 hours; you will be monitored during and after infusion.,Report any signs of allergic reaction (hives, difficulty breathing, swelling) immediately.,Seek medical help if you develop fever, chills, persistent cough, or skin changes.,Do not receive live vaccines while on AVSOLA; update vaccinations before starting.,Avoid becoming pregnant during treatment; use effective contraception.,Notify your doctor of any new or worsening symptoms, including chest pain or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENBREL vs AVSOLA, answered by our medical review team.
ENBREL is a TNF-alpha Inhibitor that works by Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.. AVSOLA is a TNF-Alpha Inhibitor that works by Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENBREL and AVSOLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENBREL is: 50 mg subcutaneous injection once weekly. The standard adult dose of AVSOLA is: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENBREL and AVSOLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENBREL is classified as Category C. Etanercept is an IgG1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birt. AVSOLA is classified as Category C. AVSOLA (infliximab-axxq) is a monoclonal antibody. IgG crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.